Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prognostic factors in multiple myeloma.

S V Rajkumar1, P R Greipp

  • 1Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.

Hematology/Oncology Clinics of North America
|January 8, 2000
PubMed
Summary

Patient survival varies greatly in myeloma. This review covers key prognostic factors, including serum beta 2-microglobulin and cytogenetics, to improve clinical practice and research outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial design.

Leukemia·2024
Same author

Daratumumab, carfilzomib, and pomalidomide for the treatment of POEMS syndrome: The Mayo Clinic Experience.

Blood cancer journal·2023
Same author

"Real-life" data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma-the Mayo Clinic experience.

Blood cancer journal·2021
Same author

Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patients.

Blood cancer journal·2021
Same author

Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial design.

Leukemia·2021
Same author

N-glycosylation of monoclonal light chains on routine MASS-FIX testing is a risk factor for MGUS progression.

Leukemia·2020

Area of Science:

  • Hematology
  • Oncology
  • Clinical Pathology

Background:

  • Multiple myeloma survival rates show considerable variability.
  • Accurate prognostic indicators are crucial for patient management and research.
  • Existing prognostic models require continuous refinement with new data.

Purpose of the Study:

  • To review established and novel prognostic factors in multiple myeloma.
  • To evaluate the evidence supporting the clinical utility of these factors.
  • To present survival data based on combinations of prognostic factors.

Main Methods:

  • Literature review of prognostic factors in multiple myeloma.
  • Analysis of evidence for clinical practice and research applications.
  • Inclusion of standard laboratory variables, cytogenetics, and novel markers like angiogenesis.

Main Results:

  • Serum beta 2-microglobulin, bone marrow plasma cell labeling index, cytogenetics, and morphology are key prognostic factors.
  • Novel factors such as bone marrow angiogenesis offer additional prognostic value.
  • Combinations of independent factors yield superior prognostic information compared to single factors.

Conclusions:

  • Prognostic factor assessment is vital for predicting multiple myeloma patient outcomes.
  • Integrating multiple independent factors enhances prognostic accuracy.
  • Continued research into novel biomarkers will further refine survival predictions.

Related Experiment Videos